Literature DB >> 11951210

Intrahepatic arterial infusion of chemotherapy: clinical results.

Don S Dizon1, Nancy E Kemeny.   

Abstract

Approximately 60% of patients diagnosed with colorectal cancer (CRC) will go on to develop hepatic metastases. Although surgical resection is the only curative modality, a majority will not be able to undergo surgery. Alternative methods for treating this population have focused on the feasibility of hepatic arterial infusion (HAI) of chemotherapy. Randomized data in this field have been hampered due to small numbers of patients in some trials, or crossover between groups. However, most trials have suggested an improvement in both overall and progression-free survival with HAI therapy. Dose-limiting toxicity associated with HAI is related to hepatobiliary sclerosis, which has been reduced with the use of dexamethasone as part of the treatment. Current research is underway to improve the rate of extrahepatic metastases in patients undergoing HAI. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11951210     DOI: 10.1053/sonc.2002.31680

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

1.  Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer.

Authors:  Lian-Xin Liu; Wei-Hui Zhang; Hong-Chi Jiang; An-Long Zhu; Lin-Feng Wu; Shu-Yi Qi; Da-Xun Piao
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

2.  The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.

Authors:  Carlo Carnaghi; Armando Santoro; Lorenza Rimassa; Roberto Doci; Riccardo Rosati; Vittorio Pedicini; Giuseppe Gullo; Monica Zuradelli; Giovanni Abbadessa; Emanuela Morenghi; Ilaria Marcon; Isabella Garassino
Journal:  Invest New Drugs       Date:  2007-05-11       Impact factor: 3.850

3.  The effect of targeted magnetic nanopaticles on hepatoma and the expression of bcl-2/bax protein.

Authors:  Jianming Wang; Baolai Xiao; Jianwei Zheng; Shengquan Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

Review 4.  Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors.

Authors:  Xiaoyu Xu; Guanghui Yang; Honglu Zhang; Glenn D Prestwich
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-08-12       Impact factor: 3.072

5.  Effect of targeted magnetic nanoparticles containing 5-FU on expression of bcl-2, bax and caspase 3 in nude mice with transplanted human liver cancer.

Authors:  Jian-Ming Wang; Bao-Lai Xiao; Jian-Wei Zheng; Hai-Bing Chen; Sheng-Quan Zou
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

6.  11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis.

Authors:  Shilin Yang; Li Jiang; Ming-Zhi Zhang
Journal:  J Oncobiomarkers       Date:  2013

7.  Inhibition of 11beta-hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans.

Authors:  Ming-Zhi Zhang; Jie Xu; Bing Yao; Huiyong Yin; Qiuyin Cai; Martha J Shrubsole; Xiwu Chen; Valentina Kon; Wei Zheng; Ambra Pozzi; Raymond C Harris
Journal:  J Clin Invest       Date:  2009-03-23       Impact factor: 14.808

8.  Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: an approach to improve the therapeutic index of highly toxic chemotherapy drugs.

Authors:  Enrico P Spugnini; Sylvie M Renaud; Sabrina Buglioni; Francesca Carocci; Emanuele Dragonetti; Raffaele Murace; Pierluigi Cardelli; Bruno Vincenzi; Alfonso Baldi; Gennaro Citro
Journal:  J Transl Med       Date:  2011-09-14       Impact factor: 5.531

9.  Loss of 11βHSD1 enhances glycolysis, facilitates intrahepatic metastasis, and indicates poor prognosis in hepatocellular carcinoma.

Authors:  Xu Liu; Xiao-Long Tan; Meng Xia; Chao Wu; Jia Song; Jing-Jing Wu; Arian Laurence; Qing-Guo Xie; Ming-Zhi Zhang; Hui-Fang Liang; Bi-Xiang Zhang; Xiao-Ping Chen
Journal:  Oncotarget       Date:  2016-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.